Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Fuva Brain Ltd. (3927:JPX), powered by AI.
Fuva Brain Ltd. is currently trading at ¥882. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Fuva Brain Ltd. on Alpha Lenz.
Fuva Brain Ltd.'s P/E ratio is 42.5.
“Fuva Brain Ltd. trades at a P/E of 42.5 (premium valuation) with modest ROE of 7.6%. 3Y revenue CAGR of 37.5% highlights clear growth momentum.”
Ask for details →Fuva Brain Ltd. is a company known for developing and distributing a variety of nutritional supplements focused on cognitive health and wellness. It primarily aims to enhance brain function and support mental well-being through its innovative product lines. The company's offerings include supplements that target memory improvement, stress reduction, and overall mental performance. These products are designed to cater to various consumer segments ranging from students to professionals seeking mental acuity and seniors looking to maintain cognitive health. With a commitment to research and development, Fuva Brain Ltd. collaborates with scientific experts to ensure evidence-backed formulations, thereby positioning itself as a trusted brand in the health and wellness industry. It plays a significant role in the dietary supplements market, contributing to the growing trend of preventative healthcare and wellness consciousness among consumers. By focusing on quality and efficacy, Fuva Brain Ltd. aims to meet the increasing demand for natural health solutions while potentially influencing the broader nutraceutical landscape.
“Fuva Brain Ltd. trades at a P/E of 42.5 (premium valuation) with modest ROE of 7.6%. 3Y revenue CAGR of 37.5% highlights clear growth momentum.”
Ask for details →Fuva Brain Ltd. (ticker: 3927) is a company listed on JPX in the Technology sector (Software - Infrastructure). It has approximately 256 employees. Market cap is $4.7B.
The current price is 882 with a P/E ratio of 42.51x and P/B of 3.03x.
ROE is 7.61% and operating margin is 4.29%. Annual revenue is $4.4B.